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ABSTRACT 
 
IL-33/ST2 axis is known to promote Th2 immune responses and has been 
linked to several autoimmune and inflammatory disorders, including inflammatory 
bowel disease (IBD), and recent evidences show that it can regulate eosinophils 
(EOS) infiltration and function. Based also on the well documented relationship 
between EOS and IBD, we assessed the role of IL-33-mediated eosinophilia and 
ileal inflammation in SAMP1/YitFc (SAMP) murine model of Th1/Th2 chronic 
enteritis, and we found that IL-33 is related to inflammation progression and EOS 
infiltration as well as IL-5 and eotaxins increase. Administering IL-33 to SAMP and 
AKR mice augmented eosinophilia, eotaxins mRNA expression and Th2 molecules 
production, whereas blockade of ST2 and/or typical EOS molecules, such as IL-5 
and CCR3, resulted in a marked decrease of inflammation, EOS infiltration, IL-5 and 
eotaxins mRNA expression and Th2 cytokines production. Human data supported 
mice’s showing an increased colocalization of IL-33 and EOS in the colon mucosa of 
UC patients, as well as an augmented IL-5 and eotaxins mRNA expression, when 
compared to non-UC. Lastly we analyzed SAMP raised in germ free (GF) condition to 
see the microbiota effect on IL-33 expression and Th2 responses leading to chronic 
intestinal inflammation. We found a remarkable decrease in ileal IL-33 and Th2 
cytokines mRNA expression as well as EOS infiltration in GF versus normal SAMP with 
comparable inflammatory scores. Moreover, EOS depletion in normal SAMP didn’t 
affect IL-33 mRNA expression. These data demonstrate a pathogenic role of IL-33-
mediated eosinophilia in chronic intestinal inflammation, and that blockade of IL-33 
and/or downstream EOS activation may represent a novel therapeutic modality to treat 
patients with IBD. Also they highlight the gut microbiota role in IL-33 production, and 
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the following EOS infiltration in the intestinal mucosa, confirming that the microbiota 
is essential in mounting potent Th2 response leading to chronic ileitis in SAMP. 
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INTRODUCTION 
The IL-33 
IL-33, also known as IL-1F11, is the newest member of the IL-1 family and 
represents a protein with dual function that can act as both a signaling cytokine as 
well as an intracellular nuclear factor (Baekkevold et al., 2003; Carriere et al., 2007).  
IL-33 was originally localized to high endothelial venules of human tonsils, Peyer’s 
patches, and lymph nodes (Baekkevold et al., 2003).  More recent reports suggest 
its wide distribution throughout various organ systems, with primary expression in 
non-hematopoietic cells, including fibroblasts, adipocytes, smooth muscle cells, 
endothelial cells, bronchial and intestinal epithelial cells (Moussion et al., 2008; 
Schmitz et al., 2005; Wood et al., 2009), but also in cells of hematopoietic origin, 
particularly in restricted populations of professional antigen presenting cells, such as 
macrophages and dendritic cells (Schmitz et al., 2005).  IL-33 was initially associated 
with the development of Th2 immunity, based on the expression of its cell-bound 
receptor, ST2L (IL-1R4), on polarized Th2 lymphocytes (Schmitz et al., 2005) and 
more recently, on innate lymphoid cells (Neill et al., 2010; Price et al., 2010), as well 
as its ability to potently induce the production of Th2 cytokines (e.g., IL-4, IL-5, and 
IL-13) in both in vitro and in vivo systems.  In regard to disease pathogenesis, IL-33 
has been shown to be involved in Th2-mediated disorders, such as airway 
inflammation (Kurowska-Stolarska et al., 2008; Kurowska-Stolarska et al., 2009; Liu 
et al., 2009) and allergic reactions (Halim et al., 2012; Komai-Koma et al., 2012; 
Matsuba-Kitamura et al., 2010); however, IL-33 has also been described to 
exacerbate arthritis, widely considered to be a Th1/Th17-mediated pathology 
(Palmer et al., 2009; Xu et al., 2008). 
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IL-33 and eosinophils 
One of the original observations and prominent functions of IL-33 is its ability 
to activate and induce the infiltration of eosinophils (EOS) into mucosal organs 
exposed to the external environment, including the respiratory and gastrointestinal 
tracts (Schmitz et al., 2005).  In fact, IL-33 has emerged as an essential mediator in 
the development of EOS-mediated allergic inflammation and asthma (Chow et al., 
2010; Stolarski et al., 2010), and plays a pivotal role in EOS recruitment and 
helminth expulsion following intestinal parasitic hookworm infection (Hung et al., 
2013).  IL-33 has been shown to potently stimulate ST2-bearing EOS to express 
CD11b and ICAM-1, produce superoxide anions, IL-6, the chemokines IL-8/CXCL8 
and MCP-1/CCL2, and promote EOS adhesiveness, degranulation, and survival 
(Cherry et al., 2008; Chow et al., 2010; Suzukawa et al., 2008a).  Importantly, EOS 
have been identified as critical players in innate immunity, expressing toll-like 
receptors (TLRs), particularly TLR7 and TLR8 (Mansson and Cardell, 2009; Nagase 
et al., 2003), and respond to both pattern- and damage/danger-associated molecular 
pattern molecules (PAMPs and DAMPs, respectively).  EOS, upon activation, can 
also produce pre- and de novo-formed factors, including granule proteins and 
cytokines/chemokines, that are important in innate responses during inflammation 
and infection (reviewed in Hogan et al., 2013).  
 
 
 
 
  7 
EOS and Inflammatory Bowel Disease 
Interestingly, a growing body of evidence also suggests the importance of 
EOS in the pathogenesis of inflammatory bowel disease (IBD), a disorder previously 
thought to occur as the result of dysregulated and overexuberant T cell responses.  
This paradigm, however, has been challenged in recent years by the concept that 
the primary cause of IBD resides in dysfunction of innate immunity (Arseneau et al., 
2007; Asquith and Powrie, 2010) and its interaction with the gut microbiota (Nell et 
al., 2010), which together shapes subsequent downstream adaptive immune 
responses.  In regard to EOS, while their numbers are reported to be elevated in 
both Crohn’s disease (CD) and ulcerative colitis (UC), two of the idiopathic forms of 
IBD (Bischoff et al., 1996; Carvalho et al., 2003), the majority of studies report the 
preponderance of EOS and EOS activity in UC compared to CD patients (Ahrens et 
al., 2008; Lampinen et al., 2008; Lampinen et al., 2005; Wallon et al., 2011).  To 
date, the mechanism(s) of action attributed to EOS in the pathogenesis of chronic 
intestinal inflammation have not been fully elucidated, although studies in animal 
models of IBD indicate that epithelial barrier disruption and damage to gut mucosal 
surfaces occur following EOS degranulation and release of EOS granule proteins, 
such as eosinophil cationic protein (ECP) and major basic protein (MBP), resulting in 
acute colitis (Forbes et al., 2004; Furuta et al., 2005; Shichijo et al., 2005; Vieira et 
al., 2009).  Other studies have suggested that EOS can also act as 
immunoregulatory cells, stimulating T cell activation and proliferation, and 
subsequent release of Th1 and Th2 cytokines (Lampinen et al., 2005; Woerly et al., 
1999), thereby perpetuating disease chronicity. 
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IL-33 and IBD 
In 2010, four independent groups reported the increased expression and 
association of IL-33 with IBD, primarily in UC and to a lesser extent in CD (Beltran et 
al., 2010; Kobori et al., 2010; Pastorelli et al., 2010; Seidelin et al., 2010).  Other 
groups have since confirmed these findings and together have established that in 
active UC, IL-33 is localized to, and potently upregulated in, intestinal epithelial cells 
and to a lesser extent, infiltrating lamina propria  (LP) mononuclear cells belonging to 
the monocyte/macrophage and B-cell lineages (Beltran et al., 2010; Pastorelli et al., 
2010).  IL-33 has also been reported to be expressed in activated subepithelial 
myofibroblasts situated below ulcerative lesions in UC patients (Kobori et al., 2010; 
Sponheim et al., 2010), indicating a potential role for IL-33 in ulcer/wound healing, 
which may be different in UC compared to CD.  In fact, although it is now widely 
accepted that IL-33 plays a central role in the pathogenesis of IBD, particularly UC, 
its precise function in this process has not been clearly defined.  Mechanistic studies 
primarily utilizing acute, chemically-induced models of colitis have resulted in 
ambiguous findings, at best, supporting both a pathogenic (Imaeda et al., 2011; 
Oboki et al., 2010; Rani et al., 2011; Sedhom et al., 2012) as well as protective 
(Duan et al., 2012; Grobeta et al., 2012) function for IL-33 in intestinal inflammation.  
To date, the IL-33/ST2 axis has not been mechanistically evaluated in a chronic, 
immunologically-mediated model of IBD. 
The SAMP1/YitFc mouse model of IBD 
The SAMP1/YitFc (SAMP) mouse strain represents a chronic model of IBD 
and provides an excellent system in which to study the contributions made by 
specific cell types to the development of enteritis, prior to the onset of inflammation, 
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during the initiation and acute phase of inflammation, and when chronic disease is 
established (reviewed in Pizarro et al., 2011).  Additionally, since SAMP mice were 
derived from brother-sister mating of WT AKR mice (parental strain) (Matsumoto et 
al., 1998), the phenotype occurs spontaneously as in the human condition, without 
chemical, genetic, or immunologic manipulation.  Inflammation is fully developed by 
10-12 wks of age (Rivera-Nieves et al., 2003), with Th1-type immune responses 
predominating early during the inductive phase (Bamias et al., 2002; Kosiewicz et 
al., 2001), and a mixed Th1/Th2 phenotype evolving as ileitis develops into chronic, 
established disease (Bamias et al., 2005).  Of note, an inherent epithelial barrier 
defect characterizes SAMP mice that occurs prior to the onset of intestinal 
inflammation and persists when SAMP are raised under germ-free (GF) conditions 
(Olson et al., 2006).   Relevant to the present study, elevated levels of serum and 
ileal IL-33 have been reported in SAMP compared to control AKR mice (Pastorelli et 
al., 2010), while adoptive transfer of SAMP CD4+ T cells into naïve SCID recipients 
results in ileitis and colitis that is abrogated by neutralizing IL-5, the major maturation 
and differentiation factor for EOS in mice and humans (Takedatsu et al., 2004). 
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PURPOSE OF THE STUDY 
In this study, we utilized the SAMP model of Th1/Th2-driven enteritis to 
mechanistically investigate whether IL-33 served any role in the development of 
chronic intestinal inflammation mediated by EOS.  Our results show that (a) EOS 
increase with the progression and severity of chronic intestinal inflammation that is 
reversed upon EOS depletion, (b) exogenous IL-33 administration induces EOS 
homing to the gut and a potent intestinal mucosal Th2 immune response, while IL-33 
blockade reduces these effects and diminishes the overall severity of disease, and 
(c) the commensal flora is essential for the induction of IL-33, subsequent EOS 
infiltration, and the production of Th2 cytokines that exacerbates ileitis characteristic 
of SAMP mice.  Taken together, these experiments demonstrate an important role 
for IL-33 in the infiltration and activation of EOS and the development of chronic 
intestinal inflammation.  As such, targeting the IL-33/ST2 axis for therapeutic 
purposes may prove to be beneficial for the treatment of IBD, particularly in patients 
with UC.  
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MATERIALS AND METHODS 
 
Animals. SAMP1/YitFC (SAMP) and AKR/J (AKR) mice were maintained 
under specific pathogen free (SPF) conditions in the Animal Resource Core Facility 
of Case Western Reserve University. GF SAMP mice where purchased from Taconic 
Farms Inc (One Hudson City Centre, Hudson, NY). All protocols were approved by 
the Institutional Animal Care and Use Committee (IACUC) of Case Western Reserve 
University. 
 
Patients.  Mucosal biopsies were obtained during ileocolonoscopy from the 
ileum and colon of adult patients with IBD. Diagnosis of UC was established by 
clinical, macroscopical, and histological criteria. Endoscopies were performed at the 
Endoscopy Unit of the 1st Dpt of Internal Medicine, Propaedeutic, at Laikon Hospital, 
Athens, Greece, and at the Gastroenterology and Endoscopy Unit of IRCCS 
Policlinico San Donato, San Donato Milanese, Milano, Italy. In most cases, samples 
were taken from the same individual both from normal-looking mucosa and from 
areas with evident inflammation. The control group consisted of individuals 
undergoing screening colonoscopy, who were included in the study only when 
endoscopy did not reveal any mucosal abnormalities. Specimens were maintained at 
4 °C for 1–2 days in RNAlater® RNA stabilization solution (Ambion Inc., CA) and then 
stored at −80 °C for total RNA extraction purpose. All diagnoses were confirmed by 
clinical, macroscopic, and histologic criteria. Full-thickness colon tissues from UC 
patients and controls were obtained as formalin-fixed, paraffin-embedded surgical 
specimens from the Pathology Department of the University Hospitals (UH) of 
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Cleveland for histology and IHC staining purpose. All studies were approved by 
Laikon Hospital and IRCCS Policlinico San Donato Ethics Committee, and by the 
Internal Review Board of the UH. 
 
Mice Timecourse and Treatments. SAMP and AKR of 4-, 12-, and-20-wk-
old were used for the timecourse study. EOS depletion was performed by 
intraperitoneal (i.p.) injection 2 times a week for 6 weeks of antibodies against 
mouse IL-5 (GS2-19-4; Lee Laboratories, Mayo Clinc, AZ) and mouse CCR3 (TRFK-
5 mAb; Lee Laboratories, Mayo Clinic, AZ) administered either singularly and 
simultaneously (5mg/Kg) on 20-wk-old SAMP mice. Control mice were treated with 
an isotype mouse IgG antibody (IR-MS-GF-ED; Innovative Research). For IL-33 
administration study 4-and 12-wk-old SAMP and AKR mice were i.p. injected with 
recombinant mouse IL-33 (ALX-522-101; Enzo Life Sciences) daily for one week 
(33µg/Kg). Control mice were injected with PBS. IL-33 neutralization was achieved 
by i.p. administration in 10-and 20-wk-old SAMP mice with an antibody against 
mST2L (mu anti-huAGP3pep-4D2 or rat anti muST2 M955, 1201 Amgen Court West 
AW2/D4262, Seattle, WA 98101-2936) 2 times a week for 6 weeks (5mg/Kg). 
Control mice were administered with an isotype antibody (4D2 mouse IgG1 mAb # 
P62382.3; 1201 Amgen Court West AW2/D4262, Seattle,WA 98101-2936). 
 
Tissue Harvest and Histologic Assessment of SAMP Ileitis. Terminal ilea 
were removed from mice, rinsed with cold PBS, opened longitudinally, and 
submerged in Bouin’s solution (LabChem). Fixed tissues were processed, paraffin-
embedded, sectioned at 3-4µm, stained with Hematoxylin & eosin (H&E), and 
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resulting ileal sections were histologically evaluated by a single pathologist in a 
blinded fashion, using a validated semiquantitative scoring system. 
 
Isolation and Culture of mesenteric lymph node (MLN) Cells. MLNs were 
collected and processed for cells isolation as follows: briefly organs were aseptically 
removed and pressed through a 70-µm cell strainer to obtain single cells 
suspensions. Lysis of erythrocytes was performed with ACK lysis buffer (Lonza). 
Resulting cells were cultured in Roswell Park Memorial Institute (RPMI) medium 
1640 with 10% FBS and 1% penicillin/streptomicyn, in the presence of immobilized 
anti-CD3 (5 µg/mL) and soluble anti-CD28 (1µg/mL) for 48-72 h. Supernatants were 
subsequently collected for further analysis. 
 
Total RNA Extraction and Reverse Transcription. Mouse ilea and 
endoscopic biopsies were placed in RNA Later (Applied Biosystems), left at 4 °C 
overnight, then frozen and stored at -80 °C. Total RNA was isolated by using the 
Rneasy kit (Qiagen) and reverse-trinscribed by using the High Capacity RNA-to 
cDNA kit (Applied Biosystem). 
 
qRT-PCR. Expression of mouse IL-33, IL-4, IL-5, IL-13, CCL11, CCL24 and 
human IL-5, CCL11, CCL24, CCL26 mRNA transcripts relative to mouse and human 
β-actin (houskeeping gene) was measured in mouse ileal tissue and in endoscopic 
biopsies using the following primers for mouse and Qiagen kits for human: mouse IL-
33 sense (5’-TCCTTGCTTGGCAGTATCCA-3’), mouse IL-33 antisense (5’-
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TGCTCAATGTGTCAACAGACCT-3’), mouse IL-4 sense (5'-
GCTAGTTGTCATCCTGCTCTTC-3'), mouse IL-4 antisense (5'-
GGCGTCCCTTCTCCTGTG-3’), mouse IL-5 sense (5’-
GCTTCTGCACTTGAGTGTTCTG-3’), mouse IL-5 antisense (5’-
CCTCATCGTCTCATTGCTTGTC-3’), mouse IL-13 sense (5'‐
TTGCTTGCCTTGGTGGTCTC-3’), mouse IL-13 antisense (5'-
GGGAGTCTGGTCTTGTGTGATG-3’) mouse CCL11 sense (5’-
TGTCTCCCTCCACCATGCA-3’), mouse CCL11 antisense (5’-
GATCTTCTTACTGGTCATGATAAAGCA-3’), mouse CCL24 sense (5’-
TGCATCTCCCCATAGATTCTGT-3’) mouse CCL24 antisense (5’-
ACTCGGTTTTCTGGAATTTTCTTG-3’), mouse β-actin sense (5’-
CAGGGTGTGATGGGAATG-3’), mouse β-actin antisense (5’-
GTAGAAGGTGTGGTGCCAGAT-3’), human IL-5 (PPH00692A-200), human CCL11 
(PPH0057B-200), human CCL 24 (PPH01162B-200), human CCL26 (PPH0163E-
200), human β-actin (330001 PPH00073E-200). RT-PCRs were performed using an 
Applied Biosystems Step Plus machine (Applied Biosystems). Reaction mixture 
consisted of 15% volume first-strand synthesis in a total volume of 20 µL that 
included Power SYBR Green core reagents (Applied Byosistems) and 500 nM final 
concentration of primers. Thermal cycling conditions were 95 °C/10 min followed by 
40 cycles of 95 °C/15 sec and 60 °C/1 min. Expression of all the genes of interest 
was normalized to β-actin. 
 
Proteins assays. For the IL-5 and CCR3 neutralization and the IL-33 
administration studies Mouse Cytokine Screen-IR 16-plex (Quansys Biosciences) 
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were used to measure IL-1α, IL-1β, IL-6, IL-12p70, IL-2, IFNγ, TNFα, IL-17, IL-4, IL-
5, IL-10, MCP-1, MIP-1α, RANTES cytokines levels in mln’s CD3/CD28 stimulated 
supernatants. Mouse IL-13 was measured by Ready-Set-Go ELISA assays 
(eBioscience cat # 88-7137-22). For the IL-33 neutralization study Ready-Set-Go 
ELISA kits (eBioscience) were used for measuring levels of the following mouse Th2 
cytokines: IL-4 (88-7044-22), IL-5 (88-7054-22), IL-10 (88-7104-22), IL-13 (88-7137-
22). 
 
Immunohistochemistry. Immunohistochemistry (IHC) staining was 
performed using a polyclonal goat anti-mouse IL-33 IgG (AF3626; R&D Systems) at 
a 1:100 dilution or goat anti-human IL-33 IgG (AF3625; R&D Systems) at a 1:50 
dilution, and a monoclonal (clone MT-14.7) rat anti-mouse MBP IgG (Lee 
Laboratories, Mayo Clinic, AZ) at a 1:500 dilution or a monoclonal (clone MM25-
82.2) mouse anti-mouse and-human EPX IgG (Lee Laboratories, Mayo Clinic, AZ) at 
a 1:500 dilution. Tissue samples from mice were fixed by immersion in Bouin’s 
solution, human samples in 10% neutral buffered formalin (Thermo Scientific), 
processed, embedded in paraffin, and 3-µm-thick sections were placed on glass 
slides. Sections were then deparaffinized and incubated in normal serum (Vector 
Labs) for nonspecific blocking. Samples were blocked for endogenous peroxidase 
activity by using 1.75% H2O2.. Antigen retrieval was performed on human samples 
heating them in microwave (2x5 min) while submerged in unmasking solution (Vector 
Labs). After incubation with primary antibodies at 4 °C, slides were rinsed in PBS 
and incubated with an appropriate biotinylated secondary antibody (Vector Labs). 
Slides were then rinsed in PBS and incubated with Vectastain ABC Kit (Vector Labs) 
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for 30 min. Immunoreactive cells were visualized by addition of a diaminobenzidine 
substrate (Vector Labs), were counterstained with hematoxylin and mounted using 
an 80% glycerol mount. All incubations were conducted at room temperature unless 
otherwise noted. Negative controls were prepared under identical condition as 
described above avoiding to put primary antibody. 
 
EOS count. EOS, stained for MBP, were counted as number of EOS/high 
power field by a single pathologist in a blinded fashion. 
 
Images acquisition. Images were obtained on an Axiophot microscope, 
captured on an Axiocam and assembled on an Axiovision Release 4.5 (Carl Zeiss, 
Inc., Thornwood, NY). The objective lenses used were a Plan-Apochromat 20X/0.60 
∞/0.17 for mice tissues and a EC-Plan-neofluor 10X/0.3 Ph1 ∞/-. 
 
Statistical analysis. Statistical analysis was performed by using, paired 
Student’s t test for paired data, and linear regression, as appropriate. 
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RESULTS 
Marked increase in EOS infiltration is associated with disease progression and 
severity in the SAMP model of chronic intestinal inflammation 
In order to determine whether EOS played an important role in the 
pathogenesis of chronic intestinal inflammation in an established Th1/Th2-driven 
model of IBD, we utilized SAMP mice and performed a detailed time course study 
comparing the presence of EOS, its correlation to disease severity, and expression 
of EOS-associated mediators in 4-, 12- and 20-wk-old SAMP with their age- and 
gender-matched parental (AKR) controls.  These distinct ages represent critical time 
points in the development of SAMP ileitis, based on phenotypic and functional 
differences as follows: 3-4 wks (prior to histologic evidence of ileal inflammation, but 
epithelial permeability defect present), 12 wks (early, active phase of inflammation 
with prominent polymorphonuclear leukocytes (PMN) infiltration, expansion of 
macrophages and lymphocytes, and dominant Th1 cytokine profile), and 20 wks 
(established, chronic inflammation with prevalence of lymphocytic and plasma cell 
infiltration, and mixed Th1/Th2 cytokine profile).  After 20 wks of age, no significant 
differences are observed in the severity of intestinal inflammation assessed by 
several parameters, including histology, percent of immune cell subsets in MLNs and 
LP, MLN cytokine profiles, and epithelial permeability (Pizarro et al., 2011).  In this 
study, EOS were identified by MBP-positivity since MBP represents one of the most 
abundant proteins produced by EOS and exists as two different homologues (i.e., 
MBP1 and MBP2), with the former produced at significantly lower levels in EOS, but 
also in basophils, while the latter is specific for EOS (Furuta et al., 2005; Woodruff et 
al., 2011). 
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Our results showed that prior to the onset of histologically-evident 
inflammation, 4-wk-old SAMP displayed sparse, scattered MBP+ cells, identified as 
EOS, within the ileal LP, similar to that observed in age-matched AKR controls, but 
with evident accumulation already present within the base of the crypts (Fig. 1, left 
panels).  By 12 wks, massive EOS infiltration was seen throughout the LP of SAMP 
ilea, with marked accumulation close to the base of the crypts, and in the deep 
submucosa immediately adjacent to the muscularis propria.  Histologically, frank ileal 
inflammation was present at 12 wks, with expansion of the LP and loss of 
conventional villous architecture (Fig. 1, lower middle panel). This phenotype 
persisted in 20-wk-old SAMP (Fig. 1, lower right panel), while age-matched AKR 
control groups showed scant numbers of EOS scattered throughout the LP with no 
histologic evidence of inflammation (Fig. 1, upper middle & right panels). 
Fig  1.    Increased infiltration of EOS is associated with the progression of disease 
severity in SAMP mice.  Representative photomicrographs of full-thickness ilea from 4-, 
12-, and 20-wk-old SAMP and AKR mice (N=4), evaluated for EOS by IHC for major 
basic protein (MBP), show sparse, scattered staining within the lamina propria of 4-wk-old 
SAMP, prior to histologic evidence of ileitis (lower, left panel), while 12- and 20-wk-old 
SAMP with established disease show a marked and progressive increase in EOS 
infiltration as disease severity escalates (lower, middle and right panels).  Little to any 
staining is observed in age-matched AKR control mice (upper panels).  All panels  X20 + 
1.25 original mag; scale bar=100µm. 
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Quantitative enumeration of EOS revealed no difference between 4-wk-old 
SAMP and AKR mice (86.50 ± 34.53 versus 80.50 ± 6.17 EOS/HPF) (Fig. 2, left 
panel), which both strains showed little to no ileal inflammation (1.33 ± 0.54, SAMP 
and 0.63 ± 0.26, AKR) (Fig. 2, middle panel).  Conversely, the number of EOS in 
SAMP ilea was vastly increased by 12 wks of age compared to AKRs (500.00 ± 
71.53 versus 69.00 ± 19.21 EOS/HPF), with an associated elevation in inflammation 
(9.13 ± 1.05, versus 1.75 ± 0.41).  These trends were sustained in SAMP compared 
to AKR ilea through 20 wks (441.00 ± 71.50 versus 53.00 ± 9.28 EOS/HPF and 8.33 
± 0.53, versus 1.50 ± 0.27), with no significant differences in eosinophilia and ileal 
inflammation versus 12-wk-old SAMP (Fig. 2, left & middle panels).  Overall, EOS 
number positively correlated with the total inflammatory scores of experimental mice 
(r = .8100) (Fig. 2, right panel), and confirmed the association of EOS infiltration and 
the severity of ileitis in SAMP mice. 
 
Fig.  2.    Increased infiltration of EOS is associated with the progression of disease 
severity in SAMP mice.  EOS count, total inflammatory score (TIS), and correlation 
between EOS count and TIS (N≥5); **p<0.01, ***p<0.001 vs. age-matched AKR controls and 
as indicated. 
 
To further characterize the importance of EOS in SAMP mice, we next 
measured prominent mediators important in EOS development and recruitment, 
including IL-5, CCL11, and CCL24.  IL-5 represents the primary factor for EOS 
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maturation and differentiation (Takedatsu et al., 2004), but is also important in EOS 
activation and recruitment (Lampinen et al., 2001; Mishra et al., 1999), while CCL11 
and CCL24, also known as eotaxin-1 and -2, respectively, are EOS-specific 
chemokines that bind to the chemokine receptor, CCR3, expressed on the surface of 
EOS and are critical for EOS recruitment (Hogan et al., 2008; Masterson et al., 
2011).  Our results showed no differences in either IL-5, CCL11, or CCL24 mRNA 
expression comparing non-inflamed, 4-wk-old SAMP to age-matched AKRs (Fig. 3).  
However, by 12 wks, IL-5 and CCL11 mRNA levels showed a 11.6- and 2.7-fold 
increase, respectively, compared to age-matched AKRs.  The most dramatic 
difference was observed at 20 wks, wherein IL-5, CCL11, and CCL24 mRNA 
transcript levels were substantially increased by 13.3-, 3.9-, and 11.4-fold, 
respectively, compared to age-matched AKRs; in fact, mRNA expression of these 
particular EOS-associated mediators were potently elevated in 20-wk-old SAMP 
compared to earlier time points evaluating younger SAMP mice (Fig. 3). 
 
Fig.  3.    Increased infiltration of EOS-associated chemokines/cytokines is associated 
with the progression of disease severity in SAMP mice.  Relative mRNA levels of the 
EOS-associated cytokines/chemokines, IL-5 and eotaxin-1 (CCL11) and -2 (CCL24), in full-
thickness ileal tissues from SAMP vs. age-matched AKR control mice (N≥5); *p<0.05, 
**p<0.01 vs. age-matched AKR controls and as indicated. 
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Taken together, these data showed that, overall, cytokines/chemokines 
associated with eosinophilia are elevated during the development of SAMP ileitis, 
and although they may be critical in the initial activation and infiltration of EOS, they 
also appear to be important in the exacerbation of chronic intestinal inflammation 
and the maintenance of established disease. 
EOS depletion potently decreases ileal inflammation in SAMP mice with 
established disease 
We next tested whether EOS 
depletion could significantly affect 
ileitis in chronically-inflamed SAMP 
mice.  Treatment with anti-IL-5 was 
previously shown to successfully 
decrease ileitis and the presence of 
granulocytes, including EOS, in 
SAMP mice (Takedatsu et al., 2004), 
while effective in vivo depletion of 
EOS has been reported following 
administration of antibodies specific for 
CCR3 (Grimaldi et al., 1999). As such, 
20-wk-old SAMP with established 
disease were treated with a 
combination of anti-CCR3 and IL-5 antibodies for a period of six wks to achieve 
complete EOS depletion, after which ileal tissues were evaluated for histologic 
evidence of inflammation, presence of EOS, as well as eotaxin mRNA expression.  
Figure 4.  EOS depletion markedly 
reduces the severity of ileitis in ilea of 
SAMP mice with established disease.   
Histologic evaluation of ilea from EOS-
depleted 20-wk-old SAMP mice compared to 
IgG-treated controls (Cont) (N≥6); *p<0.05, 
**p<0.01, ***p<0.001 vs. Cont. and as 
indicated. 
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Our results showed that treatment with either anti-CCR3 or anti-IL-5 had a moderate, 
albeit significant, effect at decreasing total inflammation (9.38 ± 1.07 and 8.63 ± 
0.92, respectively), while combination anti-CCR3/anti-IL-5 was more effective than 
either antibody administered alone at potently downregulating ileitis compared to 
IgG-treated controls (6.38 ± 0.89 versus 12.22 ± 0.78) (Fig. 4). All three treatment 
modalities primarily decreased villous and chronic inflammatory indices, while active 
and mononuclear inflammatory features did not significantly change upon single 
antibody treatment, but were reduced upon combination anti-CCR3/anti-IL-5 
administration (Fig. 4, lower panels). 
 
Histologically, control 
IgG-treated SAMP mice 
displayed severe chronic 
active ileitis characterized by 
marked villous blunting, 
increase of monocytic 
inflammatory cells, 
especially plasma cells in 
the LP, as well as active 
cryptitis and ulceration (Fig. 
5).  Upon either anti-CCR3 
or anti-IL-5 treatment, both 
the activity and severity of 
chronic ileitis showed slight 
Figure 5.  EOS depletion markedly reduces the 
severity of ileitis in ilea of SAMP mice with 
established disease.  Representative 
photomicrographs of H&E- stained ileal tissues show a 
striking improvement in overall gut morphology, with 
restoration of villous architecture and decreased 
inflammatory cell infiltrates in SAMP mice treated with 
either anti-CCR3 or anti-IL-5 neutralizing Abs alone or 
in combination compared to IgG-treated controls (Cont).  
All panels  X20 + 1.25 original mag; scale bar=100µm. 
  23 
dampening, featured by partial restoration of villi and reduction in LP inflammatory 
infiltrates, while anti-CCR3 and anti-IL-5 together led to improved restoration of 
epithelial villous structure and an impressive decrease of overall ileal inflammation 
compared to IgG-treated control mice.  
 
 
In addition, evaluation of EOS by IHC of 
MBP+ cells revealed a dramatic decrease in ileal 
EOS infiltration (Fig. 6) and the total number of 
EOS (Fig. 7) after either anti-CCR3 or anti-IL-5 
antibody administration (35.53 ± 7.95 and 23.55 ± 
5.28 EOS/HPF), which was even more impressive 
with combination anti-CCR3/anti-IL-5 treatment 
compared to IgG-treated SAMP (17.78 ± 2.39 
versus 57.00 ± 3.48 EOS/HPF) 
Moreover, anti-CCR3 and anti-IL-5 
administered either alone or together strongly 
Figure 6.  EOS depletion potently decreases EOS infiltration in ilea of SAMP mice 
with established disease.  Representative photomicrographs of MBP-stained ileal 
tissues show a marked reduction in EOS, in SAMP mice treated with either anti-CCR3 or 
anti-IL-5 neutralizing Abs alone or in combination compared to IgG-treated controls 
(Cont).  All panels  X20 + 1.25 original mag; scale bar=100µm. 
Figure 7.  EOS depletion 
potently decreases EOS 
infiltration in ilea of SAMP 
mice with established 
disease. EOS count in EOS-
depleted vs. IgG control-
treated SAMP mice (N≥6); 
*p<0.05, ***p<0.001 vs. Cont. 
and as indicated. 
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downregulated mRNA expression of ileal CCL11 by 3.4-, 1.9-, and 2.1-fold, 
respectively, while only combination anti-CCR3/anti-IL-5 treatment was effective at 
decreasing CCL24 mRNA transcripts (by 2.9-fold) compared to IgG-treated controls 
(Fig. 8).  
 
 
 
To further investigate the downstream effects of EOS depletion in chronic 
intestinal inflammation, cytokine profiles were evaluated in gut-associated lymphoid 
tissue (GALT), specifically the draining MLN, of SAMP mice following anti-
CCR3/anti-IL-5 antibody treatment (Fig. 9).  Previous studies have established that 
unfractionated, anti-CD3/anti-CD28-activated MLN cells from inflamed SAMP mice 
with advanced disease produced elevated levels of both Th1 and Th2 cytokines, 
promoting a mixed Th1/Th2 gut mucosal immune response compared control AKRs 
(Bamias et al., 2005; Kosiewicz et al., 2001; Olson et al., 2006).  Using a similar 
protocol, TCR-activated MLN cells from EOS depleted 20-wk-old SAMP were 
Figure 8.  EOS depletion potently decreases eotaxin 
expression in ilea of SAMP mice with established disease. 
eotaxin mRNA expression in EOS-depleted vs. IgG control-
treated SAMP mice (N≥6); *p<0.05, **p<0.01, ***p<0.001 vs. 
Cont. and as indicated. 
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assayed for the production of the classic proinflammatory cytokines, IL-1α, IL-1β, IL-
6, and IL-12, prototypic Th1/Th2/Th17 cytokines, and the chemokines, MCP-1, MIP-
1α, and RANTES. 
In general, classic, acute proinflammatory cytokines were trending towards a 
decreased production in which single administration of either anti-CCR3 (for IL-6) or 
anti-IL-5 (for IL-1 and IL-12) was more effective than both antibodies given together 
(Fig. 9, top row). 
Interestingly, anti-IL-5 
appeared to have a 
greater effect in reducing 
the Th1 cytokines, IFNγ 
and TNF, but not IL-2, 
while anti-CCR3 was 
more efficient a 
decreasing the Th2 
cytokines, IL-4 and IL-5, 
but had no effect on IL-13 
(Fig. 9, middle rows).  
Production of both IL-17 
and RANTES decreased 
upon either anti-IL-5 or 
anti-CCR3 treatment, while MCP-1 and MIP-1α were differentially reduced after 
either anti-CCR3 or anti-IL-5 administration, respectively (Fig. 9, bottom row).  Of 
note, for the majority of immune mediators measured, combination anti-CCR3/anti-
Figure 9.  Cytokine profiles in SAMP mice following 
EOS depletion.  Protein levels of classic proinflammatory 
(top row), Th1/Th17 and Th2, cytokines (2nd and 3rd rows), 
as well as chemokines (bottom row) in supernatants of ex 
vivo anti-CD3/anti-CD28-activated MLN cells from EOS-
depleted vs. IgG Cont.-treated SAMP mice (N≥4); *p<0.05, 
**p<0.01. 
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IL-5 treatment was less effective at decreasing cytokine production compared to 
each antibody administered alone.   
Taken together, these data show that EOS depletion by either anti-CCR3 or 
anti-IL-5, and more potently with a combination of both antibodies together, 
effectively decreased ileal inflammation in SAMP mice with established disease.  
Importantly, while EOS depletion was successfully achieved with all three 
treatments, each of the aforementioned antibodies administered separately or in 
combination had a differential effect on several immune mediators, including 
eotaxins, chemokines, and Th1 versus Th2 cytokines. 
Exogenous administration of IL-33 induces robust EOS infiltration into the ilea 
and a potent gut mucosal Th2 response 
Based on the importance of EOS in the pathogenesis of 
SAMP ileitis and our previous report demonstrating the increase of IL-33 in this IBD 
model (Pastorelli et al., 2010), we 
investigated whether IL-33 had a direct effect 
on EOS infiltration and function in the gut 
mucosa that could potentially lead to chronic 
intestinal inflammation.  We confirmed that 
IL-33 mRNA expression was upregulated in 
the ilea of 12- and 20-wk-old SAMP 
compared to age-matched AKRs, and 
potently increased with disease progression 
(4.1- and 6.8-fold, respectively, versus 4-wk-
old SAMP) (Fig. 10).   
Figure 10.  Increased expression of IL-
33 is associated with the progression 
of disease severity in SAMP mice.  
Time course of IL-33 mRNA levels in full-
thickness ilea from native SAMP and 
age-matched AKR controls (N≥9); 
*p<0.05, **p<0.01, ***p<0.001 vs. age-
matched AKR. 
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Importantly, ileal IL-33 mRNA levels positively correlated with ileal 
inflammation (Pastorelli et al., 2010) and the number of infiltrating EOS (r = .7593) 
(Fig 11).   
 
To determine whether IL-33 had the ability to induce EOS infiltration into the 
gut in the absence of background inflammation, recombinant IL-33 was administered 
to non-inflamed AKR control mice at 4 and 12 wks of age. 
Figure 11.  Increased expression of IL-
33 is associated with the progression 
of disease severity in SAMP mice.  IL-
33 mRNA levels in full-thickness ilea 
from native SAMP and age-matched 
AKR controls and correlation with EOS 
number (N=17). 
Figure 12.  Exogenous administration of rIL-33 induces EOS 
infiltration into the ilea of normal, non-inflamed AKR mice.  
Representative photomicrographs of full-thickness ilea from 4-wk-old 
AKR mice showed abundant infiltration of EOS by IHC for MBP 
following administration of rIL-33 (right panel) compared to vehicle-
treated Cont. (N=4, left panel); all panels X20+1.25 original mag, scale 
bar=100µm. 
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 Daily administration of IL-33 for one week induced robust infiltration of EOS 
into the ilea for which total EOS number was greater in both 4- and 12-wk-old AKR 
compared to vehicle controls (25.18 ± 1.70 versus 7.23 ± 0.83 and 22.89 ± 4.45 
versus 5.43 ± 0.44 EOS/HPF, respectively) (Fig. 12 & 13).  
 
 Interestingly, exogenous administration of rIL-33 to SAMP mice did not 
increase the number of infiltrating EOS 
into the ilea of 4-wk-old mice (6.93 ± 
0.85 versus 8.65 ± 3.45 EOS/HPF), 
and actually decreased EOS numbers 
in inflamed, 12-wk-old SAMP 
compared to vehicle controls (28.35 ± 
3.32 versus 50.00 ± 7.15 EOS/HPF) 
(Fig. 13), suggesting that, in the setting 
of mucosal inflammation and when 
EOS number is already high, further 
increasing IL-33 may provoke a 
negative feedback mechanism to 
downregulate EOS infiltration into the 
Figure 13.  Exogenous administration of 
rIL-33 induces EOS infiltration into the 
ilea of normal, non-inflamed AKR mice.  
EOS number (N=4) in ilea of IL-33- and 
vehicle Cont.-treated mice.  *p<0.05, 
**p<0.01, ***p<0.001 vs. vehicle Cont.-
treated mice. 
Figure 14.  Exogenous administration of 
rIL-33 induces a relevant increase in 
eotaxins mRNA expression into the ilea 
of IL-33 treated mice.  Relative mRNA 
expression of IL-5 and eotaxins in ilea of IL-
33- and vehicle Cont.-treated mice (N=5-6). 
*p<0.05, vs. AKR vehicle Cont.-treated mice. 
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gut mucosa.  This phenomenon was also observed for IL-5 mRNA transcript levels, 
wherein IL-33 administration to both mouse strains caused a decreased trend for 
local ileal IL-5 expression, while eotaxin mRNA levels were increased by 3.1- and 
2.2-fold for CCL11 and 5- and 2.6-fold for CCL24 (both AKR and SAMP, 
respectively) compared to vehicle controls (Fig. 14).  
 Exogenous IL-33 administration also had the ability to induce a potent Th2 
mucosal immune response in GALT by 
producing copious amounts of IL-4 (3.29 ± 
0.68 versus 1.39 ± 0.77 ng/ml), IL-5 (11.14 
± 1.04 versus 2.30 ± 1.08 ng/ml), IL-10 
(2.03 ± 0.80 versus 0.15± 0.10 ng/ml), and 
IL-13 (0.74 ± 0.067 versus 0.397 ± 0.060 
ng/ml) in ex vivo TCR-activated 
unfractionated MLN cells derived from 12-
wk-old SAMP after IL-33 treatment 
compared to vehicle-treated controls 
(Fig. 15). 
These data confirm the ability 
of IL-33 to strongly induce the 
infiltration of EOS into the gut mucosa, 
and report the novel finding that IL-33 potently elicits Th2 cytokine production from 
GALT in a model of chronic intestinal inflammation.  However, in the setting gut 
inflammation and when IL-33 production is high, exogenous administration of more 
IL-33 induces a potential negative feedback mechanism that appears to 
downregulate both EOS infiltration and IL-5 mRNA expression. 
Figure 15.  Exogenous administration of 
rIL-33 induces a potent Th2 response 
from draining MLN of normal, non-
inflamed AKR mice.  Th2 cytokine levels in 
supernatants of ex vivo anti-CD3/anti-CD28-
activated MLN cells from IL-33- vs. vehicle 
Cont.-treated SAMP mice (N=4-6). *p<0.05, 
**p<0.01, ***p<0.001 vs. vehicle Cont.-
treated mice. 
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Neutralization of IL-33 by blockade of ST2/IL-33R decreases EOS infiltration, 
Th2 cytokine expression, and overall severity of ileitis in SAMP mice  
To mechanistically address whether neutralization of IL-33 had the ability to 
ameliorate Th1/Th2-driven ileitis in SAMP mice, we designed two different 
experimental strategies to test the efficacy of: 1) preventing the progression of ileal 
inflammation, and 2) treating established disease.  IL-33 activity was blocked by 
administration of an antibody against the IL-33 receptor, ST2, twice weekly for a 
period of six wks to 10- (preventive protocol) and 20-wk-old (therapeutic protocol) 
SAMP mice. 
Our results showed that both neutralizing IL-33 early in the disease process, 
and treating established ileitis, was effective in downregulating ileal inflammation 
(Fig. 16 and 17). 
 
 Using the preventive protocol, anti-ST2 was effective in reducing the severity 
of ileitis by 35% compared to IgG-treated controls (6.21 ± 0.65 versus 9.62 ± 0.71).  
Similarly, although baseline inflammation was greater in older mice, therapeutically 
treating established disease with anti-ST2 was equally effective, decreasing ileitis 
severity by 29% (10.77 ± 0.65 versus 15.07 ± 0.55) (Fig. 16).  Histologically, anti-
ST2 treatment decreased inflammatory cell infiltration, improved villous structure and 
Figure 16.  IL-33 neutralization in SAMP mice 
results in decreased ileitis severity  Blockade 
of IL-33 in SAMP mice was achieved by 
administration of an anti-ST2 antibody given 
either prior to the onset of ileitis (preventive 
protocol) or during established disease 
(Histologic evaluation therapeutic protocol), both 
for a 6-wk period. Histologic evaluation 
demonstrate a marked reduction in total 
inflammation using both preventive and 
therapeutic strategies with anti-ST2- compared 
to IgG-treated Cont. (N=13-14); p<0.05, 
***P<0.001 vs. IgG-treated Cont. 
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overall gut morphology, as well as reduced the number of infiltrating EOS compared 
to IgG-treated controls (Fig. 17). 
Figure 17.  IL-33 neutralization in SAMP mice results in decreased 
ileitis severity and reduction of EOS infiltration.  Representative 
photomicrographs of H&E- and MBP-stained full-thickness ileal tissues 
demonstrate a marked reduction in total inflammation, remarkable 
improvement in villous structure and overall gut morphology, and a 
prominent decrease in infiltrating EOS using both preventive and 
therapeutic strategies with anti-ST2- compared to IgG-treated Cont.  All 
panels X20 + 1.25 original mag; scale bar=100µm. 
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A decreased trend of 3.3- and 4.6-fold was also observed for ileal IL-5 and 
CCL24 mRNA transcripts, respectively, from SAMP treated with anti-ST2 compared 
to IgG controls, particularly using the preventive protocol, while minimal changes 
were observed for CCL11 (Fig. 18).  
 
 Similarly, anti-ST2 administration 
using either a preventive or therapeutic 
approach dampened the production of the 
Th2 cytokines, IL-4 (318.67± 63.35 versus 
146.17 ± 4.96 pg/ml; therapeutic protocol), 
IL-5 (365.25 ± 28.11 versus 191.30 ± 28.07 
pg/ml; preventive protocol), and IL10 
(1766.88 ± 245.20 versus 1010.50 ± 214.84 
pg/ml; preventive protocol), but not IL-13, 
from activated MLN cells from treated SAMP 
mice (Fig. 19). 
 
Figure 18.  IL-33 neutralization in 
SAMP mice results in modulation of 
eotaxin expression.  Relative mRNA 
expression of ileal IL-5 and eotaxins 
(N≥4); *p<0.05 vs. IgG-treated Cont. 
Figure 19.  IL-33 neutralization in SAMP mice results in modulation of Th2 cytokine 
expression.  Th2 cytokine levels in supernatants of ex vivo anti-CD3/anti-CD28-
activated MLN cells (N≥4); *p<0.05, ***P<0.001 vs. IgG-treated Cont. 
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Together, these results indicate that neutralization of IL-33 in a chronic, 
Th1/Th2-mediated model of IBD is effective in decreasing overall gut inflammation, 
the infiltration of EOS, and GALT-derived Th2 immune responses. 
EOS are abundantly expressed and co-localize with IL-33 in the inflamed 
colonic mucosa of UC patients 
Previous studies have reported the widespread presence of EOS in the gut mucosa 
of patients with IBD, and that EOS infiltration and activity is particularly high in UC 
(Ahrens et al., 2008; Lampinen et al., 2008; Lampinen et al., 2005; Wallon et al., 
2011).  Likewise, several groups have recently established that IL-33 is upregulated 
in IBD, and also predominates in patients with UC (Beltran et al., 2010; Kobori et al., 
2010; Pastorelli et al., 2010; Seidelin et al., 2010).  We therefore performed 
confirmatory experiments to determine whether results obtained in the chronic, 
SAMP Th1/Th2-mediated IBD model reflects those in the human condition, 
comparing UC patients to normal controls.  IHC studies confirmed abundant 
expression of IL-33 in UC patients, which intensified as disease became more 
severe and ulcerated (Fig. 20).  
Figure 20.  IL-33 is elevated 
in the colonic mucosa of 
UC patients.  Representative 
photomicrographs of 
resected, full-thickness 
colonic tissue stained for IL-
33 showed abundant IL-33 
localized within the mucosa 
and submucosa of ulcerated, 
inflamed areas of UC 
patients.  All panels X10+1.25 
original mag; scale 
bar=100µm. 
  34 
 Diffuse IL-33 staining was observed throughout the LP, in intestinal epithelial 
cells and scattered mononuclear cells, within the inflamed gut mucosa.  In addition, 
comparable to the distribution of EOS, IL-33 was found in submucosal mononuclear 
cells accumulating in areas marginating the muscularis mucosa.  EOS localization 
was performed by IHC for eosinophil protein X (or EPX), specific for the detection of 
human EOS (Protheroe et al., 2009; Willetts et al., 2011).  Similar to the staining 
pattern in SAMP mice, EPX+ EOS were found to primarily collect at the 
mucosal/submucosal interface adjacent to the muscularis propria, and co-localized, 
but did not overlap, with cells that were positive for IL-33 (Fig. 21). 
 
Conversely, in non-inflamed controls, IL-33 staining was largely limited to 
epithelial cells with scattered staining of LP mononuclear cells, while EOS were 
sparsely present in areas close to the colonic crypts (Fig. 22 & 23). 
 
Figure 21.  EOS infiltration 
is elevated in the colonic 
mucosa of UC patients.  
Representative 
photomicrographs of 
resected, full-thickness 
colonic tissue stained for 
EPX-specific EOS showed a 
marked accumulation of EOS 
distributed at the 
mucosal/submucosal 
interface in close proximity of 
IL-33 staining.  All panels 
X10+1.25 original mag; scale 
bar=100µm. 
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Interestingly, IL-5 mRNA levels also recapitulated results obtained from IL-33 
administration studies in SAMP mice (Fig. 10-15), wherein UC non-involved areas 
expressed a 5.7-fold increase in IL-5 mRNA levels compared to non-inflamed 
controls, but were downregulated in involved areas of severe disease (Fig. 24), 
supporting the concept that in the setting of heightened inflammation, high levels of 
IL33 may incite a negative feedback mechanism to downregulate IL-5.  Conversely, 
Figure 22.  IL-33 is low in the 
colonic mucosa of  control 
patients. Representative 
photomicrographs of resected, 
full-thickness colonic tissue 
stained for IL-33. Healthy, non-
inflamed areas of control 
patients showed less IL-33, 
primarily limited to surface 
epithelial cells.  All panels 
X10+1.25 original mag; scale 
bar=100µm. 
Figure 23.  EOS infiltration is 
low in the colonic mucosa of  
control patients. 
Representative 
photomicrographs of resected, 
full-thickness colonic tissue 
stained for EPX-specific EOS. 
Healthy, non-inflamed areas of 
control patients showed  
sparsely scattered EOS 
staining,.  All panels X10+1.25 
original mag; scale bar=100µm. 
  36 
mRNA expression for the eotaxins, CCL11, CCL24, and CCL26 were all found to be 
increased by 4.3-, 1.9-, and 2.6-fold, respectively, in severely involved colonic 
biopsies from patients with UC compared to non-inflamed controls (Fig. 24). 
 
As such, the overall results obtained from UC patients regarding co-
localization of IL-33/EOS and EOS mediator expression confirm the observed trends 
found in the SAMP model of Th1/Th2-driven IBD.  In both UC patients and SAMP 
mice, IL-33 and EOS co-localize, but do not overlap, within the inflamed gut mucosa 
and uniquely accumulate in areas adjacent to the muscularis propria.  In addition, 
eotaxin expression is increased as disease becomes more severe.  
Gut microflora is essential for the induction of IL-33, EOS infiltration, and Th2 
immune responses during SAMP ileitis 
 Previous studies from our laboratory indicated that, despite being raised 
under germ-free (GF) conditions, SAMP mice develop chronic ileitis with a delayed 
Figure 24.  EOS-associated cytokines/chemokines are elevated in the colonic 
mucosa of UC patients.  Relative mRNA expression of IL-5 and eotaxin-1 (CCL11), -2 
(CCL24), and-3 (CCL26) in involved and non-involved colonic mucosal biopsies from UC 
patients compared to healthy Cont. (N≥7); p*<0.05, p***<0.001 vs. Cont. 
  37 
onset (later than 13 wks of age), lower penetrance (70%) and decreased severity 
(1/3 of mice had severe ileitis) compared to age- and gender-matched specific 
pathogen free (SPF)-reared SAMP (Bamias et al., 2007).  Interestingly, although 
TCR-activated cells from the draining MLN of GF-SAMP displayed a robust, intact 
Th1 immune response, they were unable to mount a vigorous Th2 effector response 
in the absence of bacterial flora, as shown by a dramatic decrease in IL-5, IL-13, and 
in the ratio of GATA3:T-bet compared to SPF-SAMP; this effect could be reversed 
upon exposure of fecal antigens, which resulted in expansion of a distinct population 
of IL-4 secreting mucosal lymphocytes (Bamias et al., 2007).  As such, since IL-33 is 
best known to promote Th2 immunity (Schmitz et al., 2005), we tested the 
hypothesis that the intestinal microflora may be responsible for driving the early 
induction of IL-33, leading to the infiltration of EOS and downstream Th2 immune 
responses that ultimately exacerbates ileitis in SAMP mice. 
Our results showed that 20- to 26-wk-old GF-SAMP displayed a 5.2-fold 
decrease in IL-33 mRNA levels compared to age-matched SPF-SAMP with 
comparable inflammatory scores (6.25 ± 1.60 versus 8.33 ± 0.53, n.s.) (Fig. 25). 
 
In fact, in the absence of the gut commensal flora, a dramatic decrease was 
observed in the number of infiltrating EOS in GF- compared to SPF- raised SAMP 
(22.67 ± 4.65 versus 44.10 ± 7.15 EOS/HPF) (Fig. 26 & 27). 
Figure 25.  IL-33 mRNA level is reduced in 
the ileal mucosa of GF compared to age 
matched SPF SAMP mice.  Relative ileal IL-33 
mRNA expression in 20- to 26-wk-old SPF 
compared to age matched GF SAMP mice (N=7-
8);  p***<0.001 vs SPF SAMP mice. 
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In addition, local, gut mucosal levels of Th2 
cytokines were reduced in GF versus SPF-SAMP (Fig. 28) 
by 12.7-fold, 2-fold, and 3.5-fold for IL-4, IL-5, and IL-13, 
respectively, supporting our original observation that 
SAMP Th2 effector responses are dependent on the 
presence of the gut microflora (Bamias et al., 2007).  
Importantly, we also confirmed that IL-33 induction occurs 
independently of EOS infiltration as EOS depletion by 
combination anti-CCR3/anti-IL-5 treatment did not affect 
IL-33 mRNA levels compared to IgG-treated controls (Fig. 29), suggesting that 
upregulation of IL-33 likely occurs before EOS activation and homing to the gut and 
is dependent on the presence of the intestinal microflora.   
 
 
Figure 26.  EOS infiltration, is reduced in the ileal mucosa of GF 
compared to age matched SPF SAMP mice.  Representative 
photomicrographs of MBP-stained full thickness ileal tissues from SPF and 
GF SAMP mice show a remarkable higher amount of EOS infiltrating the 
mucosa of equally inflamed areas (respectively from left to right) all panels 
X20+1.25 original mag; scale bar=100µm. 
Figure 27.  EOS 
infiltration, is 
reduced in the ileal 
mucosa of GF 
compared to age 
matched SPF SAMP 
mice.  EOS count (N= 
4-11); p*<0.05, vs SPF 
SAMP mice. 
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Together, these data indicate that the 
gut microbiota induces the production of IL-33 
that can promote EOS infiltration into the 
intestinal mucosa.  We also confirm that the 
commensal flora is responsible for the ability 
of SAMP mice to mount a vigorous Th2 
immune response that leads to the 
exacerbation of chronic ileitis in this model of 
spontaneous IBD. 
 
 
 
 
 
Figure 28.  Th2 
cytokines mRNA 
levels is reduced 
in the ileal mucosa 
of GF compared to 
age matched SPF 
SAMP mice.  
Relative ileal mRNA 
expression in 20- to 
26-wk-old GF of 
Th2 cytokines (N=7-
8); p*<0.05, 
p**<0.01, vs SPF 
SAMP mice. 
Figure 29.  IL-33 is independent 
from EOS infiltration.  Relative 
mRNA expression of IL-33 in 20-wk-
old SAMP mice treated with a 
combination of anti-CCR3 and anti-
IL5 neutralizing Abs compared to 
IgG-treated Cont. (N=7-8). 
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DISCUSSION 
 
In this work we found an association between eosinophilia and IL-33 in an IBD 
model of spontaneous ileitis, the SAMP Yit/Fc mouse. The connection between 
eosinophilia and IBD is already well documented. Especially UC, being a Th2-driven 
disease (Seidelin et al., 2010), is the IBD that shows more eosinophil-associated 
features in humans. Our group, in the other hand, found increased levels of IL-33 in 
UC patients compared to nonaffected controls (Pastorelli et al., 2010). Moreover, we 
found that gut microbiota is essential for IL-33 production and downstream EOS 
infiltration in the intestinal mucosa as well as to generate Th2 response leading to 
chronic ileitis in SAMP mice. 
EOS and IBD 
EOS are leukocytes whose main function is supposed to be killing invading 
parasites. However, in absence of parasites, activated EOS can cause tissue 
damage and inflammation as it happens in a number of well known inflammatory 
diseases associated with eosinophilia such as asthma, allergic rhinitis, atopic skin 
disease, idiopathic hypereosinophilic syndrome and IBD (Makiyama et al., 1995; 
Silberstein, 1995). The recurrent and paroxysmal fashion of the inflammation found 
in UC associated with a characteristic feature of inflammatory diseases reminiscent 
of allergy, such as activated lymphocytes, macrophages, neutrophils and EOS 
mucosal infiltration, put UC close to inflammatory disease with an allergic component 
such as bronchial asthma (MacDermott et al., 1998; Makiyama et al., 1995). In 
normal, non inflamed tissue there is a baseline level of EOS resident in the lamina 
propria which trafficking and activation may be regulated by eotaxin and IL-5 
(Matthews et al., 1998). During intestinal inflammation EOS number is highly 
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increased as shown by morphological and immunohistochemical studies that 
revealed activation of intestinal EOS in IBD (Bischoff et al., 1996; Carvalho et al., 
2003; Dubucquoi et al., 1995) and increased intestinal release of ECP, EPO and 
EPX/EDN in UC (Carlson et al., 1999). Our data in fact confirm these evidences 
showing a massive eosinophilic infiltration in inflamed ilea of mid-age to older SAMP 
compared to AKR control mice as well as in human inflamed colon of UC patients 
compared to non UC control tissues. Eotaxins and IL-5 increase accordingly in 
human, in SAMP are more elevated at older age, that is at a more established stage 
of the disease, compared to AKR mice. This could just mean that EOS activate and 
migrate at the site of inflammation independently from the influence of IL-5 and 
eotaxins at an early stage of the disease, or, maybe, that IL-33 has a role in 
activating and recruiting EOS at the site of inflammation, and indeed our IL-33 
timecourse data corroborate the latter hypothesis showing an increase that goes 
along with EOS infiltration and the overall inflammation. In a more established and 
chronic stage of the disease then, EOS should be able to produce molecules, like IL-
5 and eotaxins, necessary to recruit and activate other EOS in a positive feedback 
mechanism that perpetuates the inflammation. IL-5 in particular increases the pool of 
eotaxin-responsive cells and primes EOS to respond to CCR3 ligands (Zimmermann 
et al., 2003), in the other hand Th2 cytokines such as IL-4, IL-10, IL-13 stimulate the 
expression and production of CCR3 specific ligands such as eotaxins (Manousou et 
al., 2010; Zimmermann et al., 2003), however Th2 molecules are generally the most 
involved cytokines in EOS trafficking (Horie et al., 1997; Manousou et al., 2010; 
Moser et al., 1992). This supports again our findings of an increased number of EOS 
that infiltrates the mucosa and submucosa of colon tissues of UC patients compared 
to non-UC ones. Our data moreover clearly show that when blocking either IL-5 or 
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CCR3 there is an evident decrease in EOS infiltration and in the overall inflammation 
in ilea of mice in which the disease is already established. Theoretically combination 
of anti-IL-5 and a CCR3 antagonist is supposed to be more effective in reducing 
eosinophilia than blocking IL-5 or CCR3 alone as this would inhibit both bone 
marrow EOS maturation, mainly induced by IL-5, and their tissue accumulation, 
predominantly a CCR3 effect (Hogan et al., 2008). As a matter of fact the 
inflammation and EOS infiltration as well as eotaxin-2 levels had a marked beneficial 
effect from the additional effect of the combined blockade treatment. 
In this scenario blocking IL-5 or CCR3 may not necessarily result in a decrease of IL-
5 itself, in a mouse with an established stage of disease, in fact, besides EOS, other 
cellular types are thought to contribute to IL-5 production, during immunologically 
mediated intestinal inflammation, such as mast cells and lymphocytes (Lorentz et al., 
1999). So, probably, blocking IL-5 in an advanced stage of chronic inflammation is 
not enough to completely stop its production by all the different cell types involved, 
and actually there could be some kind of positive feedback mechanisms that induce 
a replacement of IL-5, and consequently of CCR3 too, in an attempt to continue 
promoting the expansion of EOS progenitor cells in the bone marrow, their activation 
and migration in the site of inflammation. To mention also that IL-5 indirectly 
contributes to tissue remodeling by increasing indirectly the levels of pro-fibrotic 
effector molecules, such as TGFβ and IL-13, secreted by EOS (Blyth et al., 2000; 
Cho et al., 2004; Flood-Page et al., 2003; Huaux et al., 2003; Trifilieff et al., 2001). 
That could explain the inconsistently high levels of IL-5 found in the mlns 
supernatants of SAMP treated with anti-IL-5 and anti-CCR3. On the other hand we 
found that the cytokines most affected by this blocking treatment were, maybe more 
predictably, chemokines such as MCP-1, MIP-1α and RANTES. Along with those 
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also IL-1β, IL-12p70, TNFα and IL-4 showed a decrease when treated with anti-IL-5 
or anti-CCR3 confirming that different cytokines from different compartments (IL-1 
family, Th1, Th2), which normally are involved in the inflammatory process, are 
affected by the block of two key cytokines of EOS priming, migration and activation 
such as IL-5 and CCR3. 
IL-33 as a possible trigger for eosinophilia in UC 
IL-33 role in targeting Th2 responses is quite well documented in 2005 
Schmitz work (Schmitz et al., 2005) and recently Seidelin et al. highlighted its 
function also in Th2-polarized intestinal inflammation (Seidelin et al., 2011). 
Furthermore IL-33 induces eosinophilia and EOS activation in expressing IL-8 and 
superoxide production (Cherry et al., 2008; Pecaric-Petkovic et al., 2009; Suzukawa 
et al., 2008b). Our data support and put together these findings, we found indeed a 
positive correspondence between augmented EOS infiltration in the gut mucosa and 
IL-33 mRNA relative expression in mice treated with IL-33 along with an increase in 
Th2 cytokines in the mln. The only cytokine that appears not so significantly 
increased in the mln (even having the same trend as the others), is the IL-4. This can 
find an explanation in a relatively recent work that hypothesize the presence of two 
different pathways for Th2 responses, the IL-4-dependent and the IL-33-dependent 
pathways, based on data showing that IL-33 drives a population of murine and 
human CD4+ T cells which produce mainly IL-5 and IL-13 but not IL-4 (Kurowska-
Stolarska et al., 2008). Eotaxins mRNA relative expression in the ileum was elevated 
as well, in IL-33 administered mice, giving to the whole picture also the chemotactic 
component in the site of the inflammation. In fact the IL-33/ST2 signaling pathway 
enhances the expression of CCR3 which plays an important role in recruiting EOS 
from bone marrow to the peripheral blood and then to the sites of inflammation 
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(Humbles et al., 2002) through the interaction with the eotaxins exactly. Cherry et al. 
found that IL-33 appeared to have stronger effect than IL-5 in activating EOS, to 
produce and release proinflammatory mediators, and to contribute to EOS survival 
(Cherry et al., 2008). So we, maybe hazardously, could hypothesize, then, that the 
lower IL-5 mRNA expression we found in response to IL-33 administration, can be 
due to an agonist mechanism in activating and stimulating EOS proliferation of IL-33 
towards IL-5, directly in the site of inflammation, that can lead to a negative feedback 
mechanism and consequent inhibition of IL-5 transcription. Our data, from the IL-33 
blocking through the anti-ST2 treatments, further confirmed that the IL-33/ST2 axis 
has a determinant role in eosinophilia in IBD showing decrease in the overall 
inflammation and EOS infiltration, along with a slight decrease of IL-5 and eotaxins, 
in the ileal mucosa either in early and in established disease. The notion of IL-33 as 
a Th2 polarizing cytokine is strengthened also by the fact that ST2 is expressed on 
Th2 and not on Th1 lymphocytes (Schmitz et al., 2005) (Chan et al., 2001), and, 
consistently with this, our data on mln’s Th2 cytokines showed a quite distinctive 
common trend in decrease, except for IL-13 that didn’t show any evident change, 
when we blocked the ST2 receptor. That being so, our human data supported all the 
evidences we had from mice showing an interesting correspondence between IL-33 
accumulation and EOS infiltration in the colon mucosa of UC patients greater than in 
healthy tissues. As expected, IL-5 and eotaxins mRNA expression showed the same 
trend confirming also in humans the ostensible link between eosinophilia and IBD 
(particularly UC), that is the IL-33. 
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The importance of gut microbiota 
Lastly, to confirm the strong connection between IL-33, EOS and Th2 immune 
response, we tested the hypothesis that the gut microflora is responsible for driving 
the early induction of IL-33 that leads to EOS infiltration and downstream the Th2 
immune response that exacerbates Ileitis in SAMP, based on our previous finding 
that in GF SAMP the onset of ileitis is delayed and less severe compared to age-
matched SPF SAMP mice (Bamias et al., 2007) along with a lack of Th2 effector 
response. Our results confirmed the hypothesis showing that either IL-33 and Th2 
cytokines expression and EOS infiltration were significantly lower in 20- to 26-wk-old 
GF compared to age-matched SPF SAMP mice. Also depleting EOS didn’t affect in 
any way IL-33 induction and this final finding complete the picture in which IL-33 
upregulation occurs before EOS activation and homing to the gut and depends on 
the intestinal microflora. So we can conclude that the gut microbiota promotes IL-33 
production and so EOS infiltration as well as induces a strong Th2 response that 
leads to the exacerbation of chronic ileitis in this model of spontaneous IBD. 
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CONCLUSIONS 
In this work we highlighted and strengthen the relationship between 
eosinophilia and IBD (particularly UC) in a murine model that partially resemble a 
Th2-type of IBD, the SAMP mouse, focusing on some of the most important 
molecules that drive EOS activation and migration, such as IL-5, eotaxins and Th2 
cytokines. We found them directly related between each other and furthermore we 
found IL-33 as a possible key molecule in driving EOS infiltration and subsequent 
inflammation in the gut, interacting with IL-5 and eotaxins through a Th2 driven 
mechanism and dependent on the intestinal microbiota. Taken together these 
findings demonstrate a pathogenic role of IL-33-mediated EOS infiltration and 
function in chronic intestinal inflammation and that blockade of IL-33 could represent 
a novel therapeutic modality to treat patients with IBD, especially UC. Also they 
highlight the pivotal role of the gut microbiota in inducing IL-33 production, the 
downstream EOS infiltration and the potent Th2 response that leads to chronic ileitis 
in SAMP. 
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